Dan O'Day, Gilead CEO (Getty Images)
October 29, 2020 06:51 AM EDTUpdated 07:37 AM
Coronavirus

Covid-19 roundup: Mod­er­na posts $1.1B in Covid-19 vac­cine de­posits; Gilead CEO sees po­ten­tial need for Vek­lury on a 'sea­son­al ba­sis'

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

John Carroll

Editor & Founder

Mod­er­na’s $MR­NA ex­ec­u­tive team is clear­ly itch­ing to get a near-term EUA for their Covid-19 vac­cine.

The mR­NA wun­derkind post­ed an up­date on their piv­otal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

A service from the Financial Times